SkinexFit: Lose Weight with Peptides, Under a Doctor's Care
Doctor-prescribed Wegovy® (semaglutide) & Mounjaro® (tirzepatide), guided by body composition analysis and an AI app. Our clinic is in Bintaro, South Tangerang, within easy reach of South Jakarta and West Jakarta. No crash diets, no unsupervised online drugs.
What Is SkinexFit?
SkinexFit is the peptide injection program for weight loss from Skinex Clinic Bintaro in South Tangerang, serving patients from Bintaro, Tangerang and Jakarta. The idea is simple: clinically proven GLP-1 peptide therapy, prescribed and monitored by a doctor, combined with body composition data and day-to-day support through an app. For stubborn localized fat and loose skin, we also offer body contouring with HIFU, RF and meso lipo.
Peptide injections are not a magic bullet. These medicines work best as part of a program: a medical assessment at the start, a dose that is increased gradually, a realistic eating plan and regular reviews. That is what SkinexFit is built around.
What Could You Feel?
Healthy weight loss is about more than the scale. This is what our patients most often tell us after a few months on the program.
What Are Peptide Injections for Weight Loss?
Peptide injections for weight loss are once-weekly injections of a GLP-1 peptide, either semaglutide (Wegovy®) or tirzepatide (Mounjaro®), that mimics the body's natural satiety hormone. The medicine reduces appetite and slows stomach emptying, leading to an average weight loss of 15–21% over 68–72 weeks in clinical trials. A doctor's prescription and supervision are required.
GLP-1 (glucagon-like peptide-1) is a natural peptide hormone released by the gut after you eat. Its job is to tell the brain "you are full", slow stomach emptying and help the pancreas regulate blood sugar.
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide (Wegovy®) are man-made peptides that mimic this hormone but last far longer in the body, so one injection a week is enough. Tirzepatide (Mounjaro®) goes a step further: it activates two receptors at once, GLP-1 and GIP, so its average weight-loss effect is larger.
Evidence from medical journals
We are not asking you to trust testimonials. These are figures from large randomized controlled trials (RCTs) published in The New England Journal of Medicine:
STEP 1 (semaglutide 2.4 mg / Wegovy®). 1,961 adults with obesity and without diabetes. Average loss of 14.9% vs 2.4% with placebo; 86% of participants lost ≥5%.
Wilding JPH, et al. N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
SURMOUNT-1 (tirzepatide). 2,539 adults with obesity. The 5 / 10 / 15 mg doses reduced weight by 15.0% / 19.5% / 20.9% vs 3.1% with placebo.
Jastreboff AM, et al. N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
Note: the figures above are trial averages achieved alongside lifestyle support. Individual results vary, and weight tends to return when therapy is stopped without lifestyle change (STEP 1 extension, Wilding 2022).
Wegovy® vs Mounjaro®: Two BPOM-Registered Peptides, Their Makers and Halal Status
These are the two medicines we use at SkinexFit. Both are prescription-only and should only be obtained through official channels.
| Wegovy® | Tirzepatide (Mounjaro®) | |
|---|---|---|
| Active substance | Semaglutide 2.4 mg (GLP-1 RA) | Tirzepatide (dual GIP + GLP-1 RA) |
| Manufacturer | Novo Nordisk A/S, Denmark (manufactured in Hillerød, Denmark) | Eli Lilly and Company, United States (manufactured by Eli Lilly Italia S.p.A., Italy) |
| Marketing authorization in Indonesia | BPOM Approved by BPOM in June 2024 for weight management (BMI ≥30, or ≥27 with a comorbidity). Extended in 2025 to adolescents aged ≥12 and to cardiovascular risk reduction. Example registration number (NIE), 0.25 mg pen: DKI2464695443A1. Prescription-only medicine. | BPOM BPOM registration in February 2026 (type 2 diabetes); the weight-management indication was added in July 2026. Example registration number (NIE): DKI2673402943D1 (KwikPen 10 mg). Prescription-only medicine. |
| Halal status | Not yet certified Not yet halal-certified by BPJPH/MUI (as of September 2026). The active substance is produced with recombinant DNA technology in the yeast Saccharomyces cerevisiae; excipients: disodium phosphate, propylene glycol, phenol, water. No animal-derived ingredients are mentioned in the product documents. | Not yet certified Not yet halal-certified by BPJPH/MUI (as of September 2026). The active substance is a synthesized peptide; excipients: sodium chloride, sodium phosphate, water. No animal-derived ingredients are mentioned in the product documents. |
| Frequency | Once a week, subcutaneous | Once a week, subcutaneous |
| Average weight loss (RCT) | ≈ 15% in 68 weeks (STEP 1) | ≈ 15–21% in 72 weeks (SURMOUNT-1) |
| Proven additional benefits | 20% lower risk of cardiac events (SELECT) | Improved sleep apnea (SURMOUNT-OSA), strong blood sugar control |
| Suited to | Patients who need proven heart benefit; well tolerated | Larger weight-loss targets; patients with insulin resistance or type 2 diabetes |
Beware of illegal products. The WHO issued a global alert (June 2024) on falsified semaglutide, and "peptide vials" sold online without a BPOM registration number come with no guarantee of dose, sterility or authenticity. At SkinexFit the medicine is prescribed by a doctor and injected from an original sealed pen whose registration number you can check yourself.
Body Contouring: HIFU, RF and Meso Lipo for Stubborn Fat
Body contouring is non-surgical treatment that shapes specific areas of the body, such as the abdomen, thighs, arms and waist. Peptide injections reduce total body weight, while body contouring refines what is left: stubborn localized fat and skin that has loosened after weight loss. At SkinexFit both can run within one program.
HIFU Body Slimming
Focused ultrasound energy that reaches the fat layer beneath the skin, helping to reduce localized fat while stimulating collagen for firmer skin.
Areas: abdomen, waist, thighs, arms · 60–90 minutes · no incisions
RF Body Slimming
Radiofrequency produces controlled heat that stimulates collagen and tightens tissue. A good fit for loose skin and cellulite after weight loss.
Areas: abdomen, thighs, arms, buttocks · 30–60 minutes · no needles
Meso Lipo
Injections of a lipolytic solution into small, stubborn pockets of fat. Fat breakdown happens gradually over several sessions.
Areas: double chin, jawline, waist, upper arms · 20–30 minutes · mild swelling for 1–3 days
The order we recommend. If your BMI is still high, start with the peptide program. Once your weight is close to target, the doctor assesses which areas still need shaping or tightening and then schedules HIFU, RF or meso lipo. Body contouring is not a substitute for weight loss, a healthy diet and exercise.
Why Have Peptide Injections at SkinexFit?
The medicine is the same everywhere. What changes the outcome is who supervises it, what data is used and how honest the clinic is.
Handled by doctors, not beauticians
Screening, prescribing, dose titration and side-effect reviews are carried out by doctors with 10+ years of experience. The first consultation is free, with no obligation to continue.
Body composition analysis with InBody
Fat mass, skeletal muscle, visceral fat and body water are measured with InBody, a hospital-standard body composition analyzer, at every visit. The goal is to lose fat, not muscle.
MySkinex App with AI
Progress charts, injection reminders, side-effect notes and chat with the clinic team, all from your phone. AI helps the doctor spot patterns; you are still looked after by people.
Transparent pricing
Prices per injection and per visit are published on this page. No packages that force you to pay six months up front, and no hidden fees.
Original, BPOM-registered products
Sealed Wegovy® and tirzepatide pens from official distributors. You can check the registration number yourself on the BPOM website before the injection.
A comfortable clinic in Bintaro
1 patient = 1 private room. Graha Raya Bintaro, easy to reach from South Jakarta and Soekarno–Hatta Airport. A Skinex doctor assists with your first injection; after that you can inject yourself with guidance.
How Does the SkinexFit Peptide Program Work?
Consultation & screening (free)
The doctor goes through your medical history, regular medication, pregnancy plans and goals. If needed, basic lab tests are arranged (blood sugar, liver and kidney function, lipids, thyroid).
Baseline InBody analysis
Fat, muscle and visceral fat data from the InBody device set the baseline. The doctor chooses the medicine (Wegovy® or tirzepatide) and a realistic weekly target.
First injection & education
You start on a low dose. You are shown how to inject yourself, how to eat to avoid nausea and when to contact the doctor.
Titration & monitoring through the app
The dose is increased gradually every 4 weeks according to tolerance. You log your weight and any complaints in the MySkinex App; the clinic team keeps watch.
Monthly review
Body composition is measured again with InBody, side effects are reviewed, and the dose and eating plan are adjusted. The focus is on preserving muscle mass.
Maintenance phase
Once the target is reached, the doctor plans the long-term strategy: a maintenance dose, a gradual taper or continuing with lifestyle alone, depending on your condition.
How Much Do Peptide Injections Cost at SkinexFit?
Peptide injections at SkinexFit start from about US$60 per injection (Rp1,090,000) for Wegovy® and about US$69 per injection (Rp1,250,000) for Mounjaro®, with a free doctor consultation and InBody analysis.
Prices as of November 2026 and subject to change in line with official distributor prices. US dollar figures are approximate: converted from the rupiah price at US$1 = Rp18,069 (ECB reference rate via Frankfurter, 5 November 2026) and rounded to the nearest dollar. You are charged in rupiah (IDR), so the amount in your own currency depends on your card's exchange rate. The exact price for the dose you need is confirmed in writing at your consultation, before you decide anything. Payment is per injection / per visit; there is no obligation to buy several months in advance.
Where We Are: Bintaro, South Tangerang, Close to Jakarta
The SkinexFit program is available at Skinex Clinic Bintaro, Graha Raya Bintaro, South Tangerang. Our patients come from Bintaro, Pondok Aren, Ciputat, BSD, Alam Sutera, Tangerang City, and South and West Jakarta.
Skinex Clinic Bintaro
A medical aesthetics & wellness clinic with experienced doctors, modern technology and BPOM-approved products.
5.0 Address: Ruko Althia Park AB-11, Graha Raya Bintaro, Tangerang Selatan, Banten, Indonesia From the airport: About 30 minutes from Soekarno–Hatta International Airport (CGK) by toll road Opening hours: 09:30–18:00 (closed every Tuesday) WhatsApp: +62 815-9998-032 Payment:
View on Google Maps →
Book a Free Consultation on WhatsApp
Areas we serve
Peptide Injections Jakarta
Access from South Jakarta and West Jakarta, by toll road or commuter train.
Access & info →Peptide Injections Bintaro
The clinic's location in Graha Raya Bintaro, opening hours and nearby landmarks.
Access & info →Peptide Injections Tangerang
Access from BSD, Alam Sutera, Gading Serpong and Tangerang City.
Access & info →Questions About Peptide Injections
What are peptide injections for weight loss?
Peptide injections for weight loss are once-weekly injections of a GLP-1 peptide, either semaglutide (Wegovy®) or tirzepatide (Mounjaro®), that mimics the body's natural satiety hormone. The medicine reduces appetite and slows stomach emptying. Both are registered with BPOM, Indonesia's food and drug authority, and may only be used with a doctor's prescription.
Are peptides legal in Indonesia?
Peptides are legal when they hold a BPOM marketing authorization and are prescribed by a doctor. For weight management, the registered ones are semaglutide (Wegovy®) and tirzepatide (Mounjaro®). Peptides without BPOM authorization, such as BPC-157, TB-500, CJC-1295 and retatrutide, may not be distributed as injectable medicines.
How much do peptide injections cost in Jakarta, Bintaro and Tangerang?
At SkinexFit (Skinex Clinic Bintaro, South Tangerang), peptide injections start from about US$60 (Rp1,090,000) per injection for Wegovy® and about US$69 (Rp1,250,000) per injection for Mounjaro®, as of November 2026. One injection covers one week. The 4-injection package (1 month) starts from about US$221 (Rp3,990,000) for Wegovy and about US$248 (Rp4,490,000) for Mounjaro. The doctor consultation and InBody body composition analysis are free. You are charged in rupiah; US dollar figures are approximate. The final price depends on dose strength.
Where is the nearest peptide injection clinic to South Jakarta?
SkinexFit is located at Skinex Clinic Bintaro, Ruko Althia Park AB-11, Graha Raya Bintaro, South Tangerang, directly bordering South Jakarta. The clinic is open 09:30–18:00 every day except Tuesday. Book a free consultation on WhatsApp at +62 815-9998-032.
How are GLP-1 peptides different from other peptides such as BPC-157?
Wegovy® (semaglutide) and Mounjaro® (tirzepatide) are peptides that have passed large clinical trials and hold BPOM marketing authorization for weight management. Peptides such as BPC-157, TB-500, CJC-1295 or ipamorelin have no BPOM authorization as injectable medicines and have not been proven in adequate clinical trials. SkinexFit only uses BPOM-registered peptides.
How are peptide injections different from HIFU or RF body treatments?
Peptide injections (Wegovy® or Mounjaro®) reduce total body weight by lowering appetite. HIFU and RF body treatments do not reduce body weight; they contour specific areas and tighten the skin. Many patients start with peptides and then use body contouring for the areas that remain.
Can peptide injections be combined with body contouring?
Yes. The SkinexFit doctor plans the sequence: the peptide program to bring weight down, then HIFU, RF or meso lipo for localized fat and skin that has loosened after weight loss. The schedule is set after an InBody measurement and a skin assessment.
How much does body contouring cost at SkinexFit?
As of November 2026, RF Body Slimming is about US$39 (Rp700,000) per session and Meso Lipo Body 10 cc is about US$82 (Rp1,490,000) per session. HIFU Body Slimming is priced by the size of the area and quoted during your free doctor consultation.
Are GLP-1 peptide injections safe in the long term?
Semaglutide and tirzepatide have been studied in tens of thousands of patients, and liraglutide (the previous generation) has been in use since 2010. The SELECT trial followed 17,604 patients for an average of more than 3 years with a consistent safety profile. What matters is screening for contraindications at the start and regular monitoring, which is why these medicines should not be bought on your own.
What are the common side effects?
Common · usually temporary
- Nausea (the most frequent: 44% vs 18% with placebo in the Wegovy® trial, especially when the dose is increased)
- Diarrhea (30%), vomiting (24%) or, conversely, constipation (24%)
- Bloating, belching, abdominal pain, reflux
- Fatigue, headache, dizziness
- Mild reactions at the injection site
- Temporary hair shedding when weight drops quickly
Slow dose titration and small meals greatly reduce these complaints. Most improve within 4–8 weeks.
Who is this program suitable for?
Following the BPOM label and Indonesia's National Clinical Practice Guideline (PNPK) for Adult Obesity, Ministry of Health 2025 (KMK HK.01.07/MENKES/509/2025), which uses the Asia-Pacific BMI criteria, medication is considered for adults with:
Generally suitable
- BMI ≥ 30 kg/m², or
- BMI ≥ 25 kg/m² (obesity by Asia-Pacific criteria) with at least one comorbidity: prediabetes or type 2 diabetes, hypertension, dyslipidemia, sleep apnea, PCOS, fatty liver (Ministry of Health PNPK 2025)
- Waist circumference > 90 cm (men) or > 80 cm (women) as a marker of central obesity
- The BPOM label for Wegovy® itself: BMI ≥ 30, or ≥ 27 with a comorbidity
- You have tried diet and exercise but your weight has plateaued or your appetite is hard to control
Not suitable / needs special evaluation
- Pregnant, planning a pregnancy or breastfeeding
- Personal or family history of medullary thyroid carcinoma or MEN2
- History of pancreatitis
- Type 1 diabetes, severe diabetic retinopathy
- Eating disorders (anorexia/bulimia), severe gastroparesis
- Age < 18 (requires special consideration), or a normal BMI and simply wanting to "be thin"
How long until I see results?
Appetite usually drops within the first 1–2 weeks. Meaningful weight loss is generally seen after 8–12 weeks, once the dose has been increased. In clinical trials, weight continued to fall until around months 12 to 16.
Will the weight come back if I stop?
It can, especially if eating and activity habits return to what they were. The STEP 1 extension study showed that participants who stopped without support regained about two thirds of the weight they had lost within a year. That is why SkinexFit plans a maintenance phase with the doctor rather than an abrupt stop.
Wegovy® or tirzepatide: which is better?
On average, tirzepatide produces more weight loss (SURMOUNT-5: 20.2% vs 13.7%). Semaglutide, however, has the strongest evidence of cardiovascular benefit (SELECT). The doctor chooses based on your medical condition, target, tolerance and budget, not on trends.
Do I have to inject myself?
The first injection is given at the clinic with assistance. After that, many patients are comfortable injecting themselves at home (the needle is very small, in the abdomen or thigh). If you would rather be injected at the clinic, that is possible too.
What if I feel nauseous?
Nausea is most common in the first weeks and after a dose increase. Eat small portions, avoid fatty food and stop before you feel too full. If it is bothersome, the doctor can delay the dose increase or prescribe an anti-nausea medicine.
Can it be used during pregnancy or breastfeeding?
No. Wegovy® and Mounjaro® must not be used during pregnancy. Animal studies show a risk to the fetus, and losing weight during pregnancy offers no benefit. The official labels state:
- Semaglutide (Wegovy®): stop at least 2 months before a planned pregnancy, because the medicine takes a long time to clear from the body.
- Tirzepatide (Mounjaro®): the BPOM label advises stopping at least 1 month before a planned pregnancy. It can also reduce the effectiveness of oral contraceptive pills; use a non-oral method or additional contraception (condoms) for 4 weeks after starting and after each dose increase.
- Breastfeeding: safety data in human breast milk are insufficient; not recommended.
At SkinexFit the doctor will ask about pregnancy plans and contraception before starting therapy. If you become pregnant during the program, stop the medicine immediately and contact the doctor.
Is the medicine halal?
As of September 2026 no BPJPH/MUI halal certificate has been published for either Wegovy® or Mounjaro®, so their status is "not yet certified". The product documents do not mention animal-derived ingredients. MUI Fatwa No. 30/2013 permits the use of medicines that are not yet certified when a doctor finds them medically indicated. Under Government Regulation PP 42/2024, mandatory halal certification for prescription-only medicines only takes effect on 17 October 2034. We state this plainly so you can decide for yourself.
Why not just buy it online for less?
Because you cannot know what is in it. BPOM has found falsified semaglutide and "peptide vials" without marketing authorization. Without a doctor's screening you also would not know whether you have a contraindication (for example a thyroid history or pancreatitis). The price difference is not worth the risk.
Is it covered by BPJS or insurance?
At present, GLP-1 therapy for weight loss is generally not covered by BPJS (Indonesia's national health insurance). Some private insurers may cover it when there is a diagnosis of obesity with comorbidities; we can help prepare a doctor's letter.
Scientific & Regulatory References
View the list of references & regulatory sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.
- U.S. FDA. Wegovy® (semaglutide) Prescribing Information, Novo Nordisk, 2025. accessdata.fda.gov
- U.S. FDA. Tirzepatide Prescribing Information, Eli Lilly, 2026. accessdata.fda.gov
- EMA. Wegovy® EPAR Product Information. ema.europa.eu
- BPOM (Indonesian Food and Drug Authority). Public Assessment Report, Wegovy® (semaglutide), 18 June 2024. registrasiobat.pom.go.id
- BPOM. Summary of Product Characteristics for Wegovy® as approved by BPOM, 27 May 2025. registrasiobat.pom.go.id
- BPOM. Press release on access to innovative tirzepatide therapy for metabolic disease, 4 July 2026 (in Indonesian). pom.go.id
- BPOM. Summary of Product Characteristics for Mounjaro® KwikPen (NIE DKI2673402943D1), 21 April 2026. registrasiobat.pom.go.id
- BPOM. Product checker (registration numbers). cekbpom.pom.go.id
- Ministry of Health of the Republic of Indonesia. Decree No. HK.01.07/MENKES/509/2025 on the National Clinical Practice Guideline for the Management of Obesity in Adults (in Indonesian). keslan.kemkes.go.id
- BPJPH (Halal Product Assurance Agency). Phasing of mandatory halal certification for pharmaceutical products (PP 42/2024, in Indonesian). bpjph.halal.go.id
- WHO. Medical Product Alert: falsified semaglutide, 20 June 2024.
- Indonesian Ulema Council (MUI). Fatwa No. 30 of 2013 on Medicines and Treatment (in Indonesian). PDF
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-163.